MESI mTABLET ABI, a device used for early detection of Peripheral Arterial Disease (PAD) by measuring Ankle-Brachial Index (ABI), was cleared for marketing and sales by the Food and Drug Administration in December 2020. MESI mTABLET ABI is a unique healthcare solution, integrating wireless diagnostic modules for Ankle-Brachial Index measurement, patient records, and medical apps in one system. The FDA’s decision means that healthcare professionals in the USA will get access to the latest medical technology allowing more patients to be diagnosed with Peripheral Arterial Disease, a cardio-vascular disease with severe consequences, earlier.
Peripheral Arterial Disease, coronary heart disease, and strokes are cardio-vascular diseases with the highest mortality rate. Patients with PAD have a 6-fold increased risk of dying from cardiovascular disease within 10 years compared to patients without PAD. According to the American Heart Association, PAD affects over 8.5 million Americans and over 200 million people worldwide, but the numbers are likely to be much higher, as most of the patients often do not experience traditional symptoms.
Worldwide, and in the US, cardiovascular diseases are one of the most causes of death. Early detection of the disease is crucial, as only timely treatment can prevent further complications. Unfortunately, traditional Ankle-Brachial Index measurement with the Doppler device, due to the lengthy and complex method of measurement, is still often overlooked and underperformed, despite it being one of the most important measurements from primary care onwards. With MESI mTABLET ABI, PAD detection becomes fast and simple and automated, giving the US healthcare providers opportunity to ensure early ABI measurements and timely treatment for all patients in the risk group.
With MESI mTABLET ABI, the fully automated measurement takes only 1 minute, providing comfort to the patient and reliable diagnostic results to the healthcare professional. Due to the patented 3CUFF™ and PADsense™ algorithm, a reliable diagnostic result is guaranteed even in patients with low arterial perfusion. Besides its advanced technology for detection of PAD, the MESI mTABLET ABI automatically saves the results of the measurement in the digital patient record, allowing the physician to monitor the patient’s progress over time, including providing them with a simple way to immediately share the measurement for a second opinion.
MESI mTABLET ABI is part of the MESI mTABLET comprehensive system of diagnostic modules, patient records, and medical apps. Specifics of the medical environment were taken into consideration during the development process, resulting in complete portability and flexibility of the device. The system is easy to use and can be effortlessly introduced into any medical practice, also by offering a complete digital patient database.
“With MESI mTABLET the technology available to healthcare providers shifted from descriptive (what happened?) and diagnostic (why did it happen?) to predictive analytics (what will happen?),” says Jakob Šušterič, CEO, MESI, Ltd.
About the company:
MESI, Ltd. is an innovative company located in Europe that develops and produces medical devices for diagnostic purpose. MESI is focused on simplifying diagnostics, helping clinicians discover diseases in the early stages to provide all patients with on-time and successful treatment. With strong in-house research & development and certified production facility, MESI is a trustworthy provider of connected diagnostic devices for individual practices, hospitals, and home care globally.